Lucid Group provides medical education, medical communication, strategic consultancy and digital services to clients to drive better disease and patient management.
The company has offices in London, Beaconsfield and NYC and employs over 100 people. With growth exceeding 30 per cent for the previous two years, it has built strong, sustainable partnerships with many of the world’s leading Pharma companies.
In June 2017 LDC completed an £11million minority investment in Lucid Group Communications.
Founded in 2007 by Jan Steele and Dennis O’Brien, who will both continue to lead the business, the investment is enabling Lucid to continue to build infrastructure to support its rapid growth, ensuring that its services and offerings remain of the highest quality. It also enables Lucid to build a stronger market presence in the US, where the business launched in 2016.
In addition, the investment is supporting Lucid to build its digital and creative capability, to broaden support for clients.
In 2018 Lucid Group were named Communications Consultancy of the year and Medical Educations Consultancy of the Year at the Communiqué Awards - which celebrates exceptional healthcare communications work. The award’s judging panel was “spellbound” by the group’s performance this year stating “Lucid showed a sustained growth of 30% in a year that also saw a 46% surge in headcount and introduced flexible working.” They also said the group “demonstrated the authenticity of their patient centric approach showing a true focus on patient outcomes” and were impressed with Lucid’s investment in their team.
The Communiqué Awards also saw Lucid work its magic in two other categories, one of which was The Porterhouse Medical Group Award for Excellence in Professional Education Programmes for its two-year hidradenitis suppurativa campaign for AbbVie and Lucid’s work in multiple sclerosis for Sanofi Genzyme in the Excellence in Communications via Meetings category.